HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS Standards: Another Step In Supplement Industry Transparency Evolution

This article was originally published in The Rose Sheet

Executive Summary

CVS Pharmacy is developing standards, including third-party tests, for vitamins and supplements sold in its stores. Targeted for implementation by 2019, the standards are part of a health care-focused effort in which the firm will expand its lineup of vitamins and supplements.

You may also be interested in...



Amazon Flexes E-Commerce Heft By Imposing Quality-Control Requirements For Supplements

Amazon requires firms selling supplements on its site in the US to demonstrate their products comply with FDA regulations for labeling and GMPs. Marketers that don’t submit documentation face removal of their products from the site.

CVS Trims 7% Of Supplements From Its Shelves In 'Tested To Be Trusted' Program

CVS implemented “Tested to be Trusted” third-party program for supplements six months ahead of schedule, reducing products at store shelves 7%. National drug chain confirms it will roll out more than 300 health and wellness products across six additional categories.

SIDI Supplier Protocol Update Adds To Burgeoning Self-Regulation Library

SIDI's draft protocol update incorporates changes to guide compliance with rules established by FSMA relevant to supplement firms and adds information on economically motivated adulteration and determining whether dietary ingredients are grandfathered as compliant under DSHEA.

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel